- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00172939
Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model
September 14, 2005 updated by: National Taiwan University Hospital
This current three-year proposal aims to clarify the mechanisms of melanocyte destruction and regeneration in vitiligo lesions using both traditional cell culture and skin equivalent model (organotypic culture).
Study Overview
Detailed Description
Melanocytes (MCs) are melanin-producing cells of the skin that are derived from neural crest cells.
Vitiligo vulgaris is a common depigmentation disorder resulting from destruction of functional MCs in the affected skin.
Although this disorder affects all races and occurs in approximately 1% of the world population, its pathogenesis remains obscure.
Recovery from vitiligo is initiated by the activation, proliferation, and migration of melanoblasts (MBs) to the epidermis.
The subsequent maturation of MBs leads to production of melanosomes that will be transferred to the juxtaposed keratinocytes.
The beam of a low-energy laser produces a temperature elevation of less than 0.5 ℃.
Therefore, light-mediated reaction by such laser irradiation is referred to as biostimulation.
Mitochondrial cytochrome c oxidase is considered as a photoacceptor of low-energy laser.
Low-energy He-Ne laser has numberous clinical applications.
Our previous studies showed that He-Ne laser irradiation can induce repigmentation in vitiligo vulgaris.
However, the exact mechanisms of He-Ne laser irradiation in repigmentation are not elucidated thoroughly.
In the past, we have demonstrated the coexistence of both antikertinocyte (anti-KC) and antimelanocyte (anti-MC) IgG antibodies (Abs) in vitiligo patients and explored their potential roles in vitiligo.
This current three-year proposal aims to clarify the mechanisms of melanocyte destruction and regeneration in vitiligo lesions using both traditional cell culture and skin equivalent model (organotypic culture).
In the first year, we shall focus on the regeneration of MCs and MBs by He-Ne laser with or without the presence of anti-MC IgG antibodies from vitiligo patients, as well as the involved photodynamic mechanisms.
Our goal for the second year is to investigate the regeneration of MCs and MBs by He-Ne laser with or without the presence of anti-KC IgG antibodies from vitiligo patients.
In the final year of our project, we shall explore the effects of He-Ne laser combine antibody-dependent cellular cytotoxicity (ADCC) on the regeneration of MCs and MBs.
Our results will provide more information for the effectiveness of He-Ne laser irradiation in treating vitiligo.
Study Type
Interventional
Enrollment
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Hsin-Su Yu, MD PHD
- Phone Number: 886-2-23562141
- Email: dermyu@ha.mc.ntu.edu.tw
-
Principal Investigator:
- Chun-Hsuan Ho, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- healthy adults and patients with vitiligo
Exclusion Criteria:
- systemic disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
foreskin from normal adults
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Hsin-Su Yu, MD PHD, National Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2005
Primary Completion
December 7, 2022
Study Completion
January 1, 2008
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 14, 2005
First Posted (Estimate)
September 15, 2005
Study Record Updates
Last Update Posted (Estimate)
September 15, 2005
Last Update Submitted That Met QC Criteria
September 14, 2005
Last Verified
March 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9461700332
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.